FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer

By N. Turner, A. Pearson, R. Sharpe, Maryou B. K. Lambros, F. Geyer, M. López-García, R. Natrajan, C. Marchiò, Elizabeth Iorns, A. Mackay and 5 more. Cancer Research, 2010

695 citations recorded by the source corpus.

Amplification of FGFR1 occurs in approximately 10% of breast cancers and is associated with poor prognosis. However, it is uncertain whether over-expression of FGFR1 is causally linked to the poor prognosis of amplified cancers. Here, we show that FGFR1 over-expression is robustly associated with FGFR1 amplification in two independent series of breast cancers. Breast cancer cell lines with FGFR1 over-expression, and amplification, show enhanced ligand dependent signalling, with increased activation of the MAPK and PI3K-AKT signalling pathways in response to FGF2, but also show basal ligand independent signalling, and are dependent on FGFR signalling for anchorage independent growth. FGFR1 amplified cell lines demonstrate resistance to 4-OH-Tamoxifen, that is reversed by siRNA silencing of FGFR1, suggesting that FGFR1 over-expression also promotes endocrine therapy resistance. FGFR1 signalling suppresses progesterone receptor (PR) expression in vitro and likewise amplified cancers are frequently PR negative, identifying a potential biomarker for FGFR1 activity. Furthermore, we show that amplified cancers have a high proliferative rate assessed by Ki67 staining, and that FGFR1 amplification is found in 16-27% of luminal B type breast cancers. Our data suggests that amplification and over-expression of FGFR1 may be a major contributor to poor prognosis in luminal type breast cancers, driving anchorage independent proliferation and endocrine therapy resistance.

Subfields: Cancer Research, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/13ca2acb93ec3b21a901c11c830790347f2b091c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

In Oncology

Citations in the corpus

The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing (2015, background): “There is also evidence that there are FGFR alterations that confer resistance to other types of cancer treatment (6, 7) and that some specific FGFR aberrations may demonstrate differential sensitivity/resistance to distinct FGFR inhibitors (50).”
Genomic Evolution of Breast Cancer Metastasis and Relapse (2017, background): “FGFR1 activation and TP53 pathway inactivation (including MDM2/4 activation) have previously been associated with endocrine resistance (Ellis et al., 2012; Turner et al., 2010).”